Neuropsychiatric safety should be a key consideration in any clinical risk–benefit assessment associated with GLP1 anti-obesity medications and the analysis provided here contribute to thoughtful and objective decision-making and dialogue between patients and clinicians. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.